Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of RH109 COVID-19 mRNA Vaccine Booster
NCT05366296Phase 1Withdrawn
- Sponsor
- Wuhan Recogen Biotechnology Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Prophylactic Vaccines, mRNA Therapeutics
01
Overview
Phase 1, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing RH109 with Placebo (2 arms). Primary endpoints: Occurrence of solicited local and systemic adverse events at 7 days, Occurrence of unsolicited adverse events at 28 days and 1 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05366296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366296.